PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer
Pilot Trial of PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer
Sponsor: Memorial Sloan Kettering Cancer Center
A NA clinical study on Esophagogastric Cancer, this trial is completed. The trial is conducted by Memorial Sloan Kettering Cancer Center and has accumulated 14 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
14 versions recorded-
Jan 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Jan 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jul 2023 — Jul 2024 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Jan 2023 — Jul 2023 [monthly]
Active Not Recruiting NA
▶ Show 9 earlier versions
-
Jan 2022 — Jan 2023 [monthly]
Active Not Recruiting NA
-
Jan 2021 — Jan 2022 [monthly]
Active Not Recruiting NA
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Feb 2020 — Sep 2020 [monthly]
Recruiting NA
-
May 2019 — Feb 2020 [monthly]
Recruiting NA
-
Jun 2018 — May 2019 [monthly]
Recruiting NA
-
Jun 2017 — Jun 2018 [monthly]
Recruiting NA
-
Feb 2017 — Jun 2017 [monthly]
Recruiting NA
-
Jan 2017 — Feb 2017 [monthly]
Recruiting NA
First recorded
Dec 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Memorial Sloan Kettering Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .